Search

Your search keyword '"Feliciano, Josephine L."' showing total 190 results

Search Constraints

Start Over You searched for: Author "Feliciano, Josephine L." Remove constraint Author: "Feliciano, Josephine L."
190 results on '"Feliciano, Josephine L."'

Search Results

1. Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy

2. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

4. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non‐Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)

10. Clinician Perceptions of Barriers and Facilitators for Delivering Early Integrated Palliative Care via Telehealth

11. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer

12. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

13. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

14. Association of area‐level mortgage denial and guideline‐concordant non‐small‐cell lung cancer care and outcomes in the United States.

15. Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases

17. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis

19. Abstract 3374: Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer

20. Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases

21. Interventions for Breathlessness in Patients With Advanced Cancer

22. Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

23. Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy

24. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

27. An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis

28. Abstract 1973: Patients with operable esophageal cancer and improved responses to combined chemoradiotherapy and immunotherapy display distinct microbiome profiles enriched in multiple Bacteroides species

29. Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of biomarker-driven therapy

31. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC

33. Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US ��� updated analyses with additional trial follow-up

34. Cost-effectiveness of Pembrolizumab + Chemotherapy versus Chemotherapy and Pembrolizumab Monotherapy in 1st Line Treatment of NSCLC in the U.S. ��� updated analyses with additional trial follow-up

35. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy

36. QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events

41. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

42. Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729)

43. Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial

47. Cost-effectiveness of pembrolizumab+chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.

48. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the 1st-line treatment of squamous NSCLC in the U.S

Catalog

Books, media, physical & digital resources